Genmab A/S (GNMSF) Projected to Post Quarterly Earnings on Thursday

Genmab A/S (OTCMKTS:GNMSF) is expected to issue its resultson Thursday, May 7th. Analysts expect the company to announce earnings of $1.56 per share and revenue of $905.7740 million for the quarter.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by ($2.55). The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

Genmab A/S Stock Up 2.2%

OTCMKTS GNMSF opened at $261.00 on Tuesday. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The company has a fifty day moving average of $275.89 and a two-hundred day moving average of $301.49. The firm has a market capitalization of $16.07 billion, a price-to-earnings ratio of 16.86 and a beta of 0.82. Genmab A/S has a 52 week low of $188.80 and a 52 week high of $352.00.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.